Graves Orbitopathy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited

The Graves Orbitopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Orbitopathy pipeline products will significantly revolutionize the Graves Orbitopathy market dynamics.

DelveInsight's "Graves Orbitopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves Orbitopathy, historical and forecasted epidemiology as well as the Graves Orbitopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Graves Orbitopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Graves Orbitopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Orbitopathy Market Forecast
https://www.delveinsight.com/sample-request/graves-orbitopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Graves Orbitopathy Market Report:
• The Graves Orbitopathy market size was valued approximately USD 2,340 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to developing and commercializing potential best-in-class treatments for serious and rare conditions, has announced encouraging long-term durability results from the Phase 3 THRIVE clinical trial of veligrotug ("veli"). Veli is an intravenously administered antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) and is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, tissue expansion, and damage around and behind the eyes.
• In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company specializing in the development of oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from its Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company's lead oral small molecule candidate, is administered twice daily and is currently in clinical development for TED. It targets the well-established IGF-1R pathway and has demonstrated a favorable safety profile, having been studied in over 900 patients across fifteen clinical trials in various therapeutic areas.
• In September 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to discovering and developing potential best-in-class treatments for serious and rare diseases, today announced promising topline results from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug. This intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, growth, and damage to the tissues surrounding and behind the eyes
• The Graves' orbitopathy market in the US was valued at around USD 2,114.5 million in 2023 and is expected to grow with the introduction of new therapies.
• In 2023, the combined market size of the EU4 and the UK was estimated at around USD 203.7 million, representing nearly 9% of the total market revenue for the 7MM.
• In 2023, Germany led the market within the EU4 and the UK, with revenue of about USD 45.4 million. France was next with roughly USD 41.8 million, followed by the UK at approximately USD 40.8 million.
• In 2023, Japan's total market size for Graves' orbitopathy was estimated at around USD 22.3 million, with expectations for growth throughout the forecast period (2024-2034).
• It is estimated that VRDN-003 will generate around USD 1,473.1 million in the 7MM by the year 2034.
• As per DelveInsight's estimates, around 1.5 million diagnosed prevalent cases of Graves' orbitopathy were reported across the 7MM in 2023. Among these, the United States contributed approximately 44% of the cases, EU4 and the UK together accounted for nearly 49%, and Japan made up the remaining 7%.
• Viridian Therapeutics' VRDN-003, an IGF-1R-targeting antibody, is currently undergoing Phase III clinical trials, with plans to submit a Biologics License Application (BLA) in the US for the treatment of Graves' orbitopathy by the end of 2026.
• According to DelveInsight, approximately 7.1 million individuals were affected by Graves' disease in the 7MM in 2023, with around 3.7 million diagnosed cases. These figures are expected to increase by 2034.
• In 2023, the United States reported the highest number of diagnosed prevalent cases of Graves' orbitopathy, with an estimated 643,000 cases. This number is expected to rise throughout the 2020-2034 study period.
• In 2023, Germany led the EU4 and the UK in diagnosed prevalent cases of Graves' orbitopathy, reporting approximately 162,000 cases, followed by France with around 149,000 cases. Spain recorded the lowest number, with about 128,000 cases.
• In 2023, Japan reported nearly 102,000 diagnosed prevalent cases of Graves' orbitopathy.
• In 2023, the US recorded approximately 129,000 diagnosed prevalent cases of Graves' orbitopathy in males and 514,000 cases in females.
• Key Graves Orbitopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others
• Key Graves Orbitopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
• The Graves Orbitopathy epidemiology based on gender analyzed that the females are affected more as compared to males in the case of Graves Orbitopathy

Graves Orbitopathy Overview
Graves Orbitopathy, also known as Thyroid Eye Disease (TED), is an autoimmune inflammatory disorder affecting the eye muscles and surrounding tissues. It is most commonly associated with Graves' disease, a type of hyperthyroidism. The condition can cause eye bulging (proptosis), double vision, pain, redness, and in severe cases, vision loss. Inflammation and tissue remodeling behind the eyes lead to these symptoms. Early diagnosis and management are crucial to prevent complications. Treatment options include corticosteroids, immunosuppressive therapy, radiation, and in some cases, surgery.

Get a Free sample for the Graves Orbitopathy Market Report -
https://www.delveinsight.com/report-store/graves-orbitopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Orbitopathy Market
The dynamics of the Graves Orbitopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
"The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated."

Graves Orbitopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Graves Orbitopathy Epidemiology Segmentation:
The Graves Orbitopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Prevalent Cases of Graves Orbitopathy in the 7MM
• Diagnosed Prevalent Cases of Graves Orbitopathy in the 7MM
• Gender-specific Diagnosed Prevalent Cases of Graves Orbitopathy in the 7MM
• Moderate-to-severe Drug-treated Cases of Acute Graves Orbitopathy in the 7MM
• Acute Diagnosed Prevalent Cases of Graves Orbitopathy in the 7MM
• Diagnosed Prevalent Cases of Graves Orbitopathy by Chronicity in the 7MM

Download the report to understand which factors are driving Graves Orbitopathy epidemiology trends @ Graves Orbitopathy Epidemiological Insights
https://www.delveinsight.com/sample-request/graves-orbitopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Orbitopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Orbitopathy market or expected to get launched during the study period. The analysis covers Graves Orbitopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graves Orbitopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves Orbitopathy Therapies and Key Companies
• VRDN-003: Viridian Therapeutics
• Efgartigimod PH20 SC: Argenx
• Batoclimab (IMVT 1401): Immunovant Sciences
• RVT-1401: Immunovant Sciences GmbH
• Teprotumumab: Horizon Pharma USA, Inc.
• VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.
• Batoclimab: Immunovant Sciences GmbH
• TOUR006 - 20 MG: Tourmaline Bio, Inc.
• IBI311: Innovent Biologics (Suzhou) Co. Ltd.
• lonigutamab: ACELYRIN Inc.
• Satralizumab: Hoffmann-La Roche
• TEPEZZA: Horizon Therapeutics USA, Inc.
• LASN01: Lassen Therapeutics Inc.
• CFZ533: Novartis
• linsitinib: Sling Therapeutics, Inc.
• LASN01: Lassen Therapeutics

To know more about Graves Orbitopathy treatment, visit @ Graves Orbitopathy Medications
https://www.delveinsight.com/sample-request/graves-orbitopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Graves Orbitopathy Market Strengths
• The recent US FDA approval of Horizon's TEPEZZA has accelerated the research and development of GO.
• Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.

Graves Orbitopathy Market opportunities
• Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.
• Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.

Scope of the Graves Orbitopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Graves Orbitopathy Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others
• Key Graves Orbitopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
• Graves Orbitopathy Therapeutic Assessment: Graves Orbitopathy current marketed and Graves Orbitopathy emerging therapies
• Graves Orbitopathy Market Dynamics: Graves Orbitopathy market drivers and Graves Orbitopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Graves Orbitopathy Unmet Needs, KOL's views, Analyst's views, Graves Orbitopathy Market Access and Reimbursement

Discover more about therapies set to grab major Graves Orbitopathy market share @ Graves Orbitopathy Treatment Landscape
https://www.delveinsight.com/sample-request/graves-orbitopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Graves Orbitopathy Market Report Introduction
2. Executive Summary for Graves Orbitopathy
3. SWOT analysis of Graves Orbitopathy
4. Graves Orbitopathy Patient Share (%) Overview at a Glance
5. Graves Orbitopathy Market Overview at a Glance
6. Graves Orbitopathy Disease Background and Overview
7. Graves Orbitopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Graves Orbitopathy
9. Graves Orbitopathy Current Treatment and Medical Practices
10. Graves Orbitopathy Unmet Needs
11. Graves Orbitopathy Emerging Therapies
12. Graves Orbitopathy Market Outlook
13. Country-Wise Graves Orbitopathy Market Analysis (2020-2034)
14. Graves Orbitopathy Market Access and Reimbursement of Therapies
15. Graves Orbitopathy Market Drivers
16. Graves Orbitopathy Market Barriers
17. Graves Orbitopathy Appendix
18. Graves Orbitopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Graves Orbitopathy Pipeline https://www.delveinsight.com/report-store/graves-orbitopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Graves Orbitopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graves Orbitopathy market. A detailed picture of the Graves Orbitopathy pipeline landscape is provided, which includes the disease overview and Graves Orbitopathy treatment guidelines.

Graves Orbitopathy Epidemiology https://www.delveinsight.com/report-store/graves-orbitopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Graves Orbitopathy Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Graves Orbitopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market
• Arteriovenous Malformations Market: https://www.delveinsight.com/report-store/vascular-malformations-market
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.